Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer

Summary

COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC). The study investigates whether a risk-adapted, compartmentalized radiotherapy strategy can safely reduce the treatment volume, and thus the side effects, without increasing the risk of tumor recurrence. Eligible patients are those with surgically treated cancers of the oral cavity, oropharynx, larynx, or hypopharynx who have a standard indication for postoperative radiotherapy. The primary outcome is the rate of recurrence in anatomical compartments that would normally be irradiated but are intentionally omitted in this study. COMPORT aims to generate high-level evidence to support a more personalized and less toxic standard of care in postoperative head and neck cancer management.

Conditions

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma

Interventions

RADIATION

Compartmentalized Postoperative Radiotherapy

Pathology- and imaging-guided compartmentalized postoperative radiotherapy (PORT), with or without concurrent systemic treatment. Based on a predefined algorithm, PORT or specific anatomical volumes may be omitted. Dose prescription and volumes are risk-adapted.

Sponsors & Collaborators

• Clinical Trials Unit, Bern, Switzerland

  collaborator UNKNOWN

• Fond'action contre le cancer

  collaborator UNKNOWN

• University Hospital, Zürich

  collaborator OTHER

• University Hospital, Basel, Switzerland

  collaborator OTHER

• Kantonsspital Aarau

  collaborator OTHER

• Oncology Institute of Southern Switzerland

  collaborator OTHER

• Insel Gruppe AG, University Hospital Bern

  collaborator OTHER

• Olgun Elicin

  lead OTHER

Principal Investigators

• Timo Nannen · Inselspital, Bern University Hospital and University of Bern

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-01-15

Primary Completion

2029-01-31

Completion

2029-04-30

Countries

• Switzerland

Study Locations